GlassScriptPhysician profile
Keoni Nguyen
NPI 1831388198
$2,560.40
in general payments reported to CMS, 2019-2025
12 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $332 · 2021: $38.91 · 2022: $12.54 · 2023: $30.83 · 2024: $172 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,529 · Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,529.17 |
| Food and Beverage | $647.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $1,671.15 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Abbvie INC. | $332.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $160.56 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $121.83 | 2020-2025 | |
| Genzyme Corporation | $83.97 | 2020 | |
| Lilly USA, LLC | $68.13 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $31.56 | 2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $27.08 | 2025 | Ycanth |
| Amgen INC. | $19.17 | 2025 | Otezla |
| Incyte Corporation | $17.36 | 2025 | Opzelura |
| Ucb, INC. | $14.79 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keoni Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.